Structure Therapeutics Inc. (GPCR)

NASDAQ: GPCR · Real-Time Price · USD

19.77

-0.17 (-0.85%)

At close: Mar 28, 2025, 4:00 PM

19.47

-0.30 (-1.51%)

After-hours: Mar 28, 2025, 7:00 PM EDT

Structure Therapeutics Employees

Structure Therapeutics had 163 employees as of December 31, 2024. The number of employees increased by 70 or 75.27% compared to the previous year.

Employees

163

Change (1Y)

70

Growth (1Y)

75.27%

Revenue / Employee

n/a

Profits / Employee

-$751,693

Market Cap

1.13B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	163	70	75.27%
Dec 31, 2023	93	25	36.76%
Dec 31, 2022	68	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

GPCR News

3 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
10 days ago - Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate - Seeking Alpha
2 months ago - Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences - GlobeNewsWire
2 months ago - Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst - Benzinga
3 months ago - Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - GlobeNewsWire
4 months ago - Structure Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
4 months ago - Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity - GlobeNewsWire
5 months ago - Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients - Seeking Alpha